Dual optic accommodating IOL offers good quality of life

Article

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

They conducted a non-concurrent case series involving four patient groups implanted with multifocal IOLs or dual optic accommodating lenses: Alcon's Acrysof ReSTOR (n=27), AMO's ReZoom (n=28), AMO's Tecnis multifocal (n=34) and Visiogen's Synchrony dual optic accommodating IOL (n=31).

Subjects were matched based on age at time of implant and the absence of ocular co-morbidity. An adapted VF-7 questionnaire was completed by subjects three and six months after the second eye had received the implant and a questionnaire regarding halo and glare sensitivity was also mailed to all subjects.

The preoperative VF-7 scores ranged from 33.4 to 37.5 for all four groups. At six months follow-up, the mean VF-7 scores were 78.4 in the ReSTOR group, 81.7 in the Tecnis group, 71.5 in the ReZoom group and 84.2 in the Synchrony group. Halos occurred most often in the ReZoom group (21%) and least often in the Synchrony group (6.4%).

Glavis and Ossma concluded from their study that the dual optic accommodating IOL, Synchrony, not only offers patients a better quality of life, but it also yields a greater range of vision when compared to multifocal lenses.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.